

## Drug Monograph

Drug/Drug **Diazepam (diazepam) Solution / Benzodiazepine**

Class:

Prepared for: MO HealthNet

Prepared by: ACS, A Xerox Company

**New Criteria**

**Revision of Existing Criteria**

### Executive Summary

**Purpose:** The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.

**Dosage Forms:** Each 5 mL unit dose cup contains 5 mg of diazepam.

**Manufacturer:** Roxane Laboratories, Inc. Columbus, OH 43216

**Indications:** Diazepam is indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety, adjunct treatment for the relief of skeletal muscle spasm, adjunctive treatment in convulsive disorders and may be useful in the symptomatic relief of acute agitation, tremor, impending or acute delirium tremens and hallucinations associated with acute alcohol withdrawal.

**Costs:** \$3.85 per 5mL unit dose cup of diazepam solution Wholesale Acquisition Cost

**Summary of Findings:** MO HealthNet Division recommends Open Access status for this product.

**Status Recommendation:**  Prior Authorization (PA) Required  Open Access  
 Clinical Edit  PDL

**Type of PA Criteria:**  Increased Risk of ADE  No PA Required  
 Appropriate Indications  Under Solicitation

Prepared By: Katie Wilbers, Pharm.D.  
 Date: June1, 2012